Clinical Trial on Treatment of Intraventricular Hemorrhage

Phase 2

Completed

• Conditions: Intraventricular Hemorrhage
• Interventions: Drug: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)

• Registration Number: NCT00650858
• Lead Sponsor: Johns Hopkins University

Brief Summary

The specific objective of this trial is to determine the lowest dose and dose frequency possible with the best pharmacokinetic and safety profile and it's ability to remove a blood clot from the ventricular system.

Detailed Description

The purpose of this trial is to determine the efficacy and pharmacokinetics of intraventricular injections of multiple low doses of rt-PA. Sixteen subjects were already randomized to receive intraventricular injections of with 0.3 mg or 1.0 mg of rt-PA every 12 hours for up to 8 doses. Results of this stage (n=16) were then analyzed and the most effective dose of 1.0 mg was chosen to be used in the second stage (n=36) to determine the optimal frequency of dosing. We propose to test if this intervention facilitates more rapid clot resolution, complete recovery function and decreased mortality from this condition.

Study Timeline

• Study Start: 2004-02
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2008-04-01
• Study First Posted: 2008-04-02
• Primary Completion: 2008-08
• Study Completion: 2008-08
• Results First Submitted: 2009-03-12
• Results First Submitted QC: 2012-06-13
• Results First Posted: 2012-07-17
• Status Verified: 2017-11
• Last Update Submitted: 2017-11-08
• Last Update Posted: 2017-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

1. Age 18-75
2. IVC placed as standard of care using less than or equal to 2 complete passes.
3. Spontaneous ICH less than or equal to 30 cc.
4. Able to receive first dose within 48 hours of CT scan diagnosing IVH (providing the time of symptom onset to diagnostic CT does not exceed 12 hours).
5. Clot size measured on CT scan done 6 hours after IVC placement must be equal to the presentation clot size plus or minus 5 cc (as determined by the AxBxC)/2 method).
6. ON stability CT scan either the 3rd or 4th ventricles are occluded with blood (no evidence of CSF flow on CT).
7. SBP < 200 mmHg sustained for 6 hours.
8. Historical Rankin of 0 or 1.

Exclusion Criteria

1. Suspected or untreated aneurysm or AVM (unless ruled out by angiogram or MRA/MRI).
2. Clotting disorders.
3. Patients with platelet count < 100,000, INR > 1.7, PT > 15s, or an elevated APTT.
4. Pregnancy (positive pregnancy test).
5. Infratentorial hemorrhage (i.e., parenchymal/posterior fossa hematoma; all cerebellar hematomas excluded).
6. SAH (An angiogram should be obtained when the diagnostic CT scan demonstrates subarachnoid hemorrhage or any hematoma location or appearance not strongly associated with hypertension. If the angiogram does not demonstrate a bleeding source that accounts for the hemorrhage, the patient is eligible for the study).
7. ICH enlargement during the 6-hour stabilization period (6 hour after IVC placement).
8. Internal bleeding, involving retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts.
9. Superficial or surface bleeding, observed mainly at vascular puncture and access sites (e.g., venous cutdowns, arterial punctures) or site of recent surgical intervention.
10. Known risk for embolization, including history of left heart thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, and subacute bacterial endocarditis.
11. Prior enrollment in the study.
12. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
13. Participation in another simultaneous medical investigation or trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1.0 mg Rt-PA q8h	tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)	In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
0.3 mg rt-PA	tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)	In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
1.0 mg rt-PA	tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)	In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.

Primary Outcome Measures

Name	Time	Method
30-day Mortality	30 days	The number of subjects who died at or before the 30-day follow-up visit were determined as a measure of safety. If more than 50% of the subjects died at or before the 30-day follow-up visit, the study would have been stopped for full DSMB review.
Rate of Symptomatic Bleeding Events	30-days	The rate of symptomatic brain bleeding events were recorded to determine the safety of intraventricular administrations of rt-PA. If 35% or more subjects experienced a symptomatic bleeding event prior to the 30-day follow-up visit, the study would have been stopped for a full DSMB review.
Incidence of Bacterial Ventriculitis, Meningitis	30 days	The incidence of bacterial ventriculitis/meningitis was recorded to determine the safety of intraventricular administration of rt-PA. If 30% or more subjects experienced this event, the study would have been stopped for full DSMB review.

Secondary Outcome Measures

Name	Time	Method
Average Daily Percentage Clot Size Resolution Over the First 3 Days	3 days	Daily IVH clot volume resolution, as a percentage of stability CT IVH volume, averaged over the first 3 days, determined by CT scans
90 Day Follow-Up Glasgow Outcome Scale (GOS) Score	90 days	90 day follow-up visit GOS score. The GOS is a scale used to determine the degree of recovery from patients with brain injury. There are five categories: 1. Dead, 2. Vegetative State, 3. Severe Disability, 4. Moderate Disability and 5. Good Recovery.; (Stage 1 patients only had 30 day scores, Stage 2 patients had 30 day, 90 day and 180 day scores collected)
90 Day Follow-Up Modified Rankin Scale (mRS) Score	90 days	90 day follow-up visit mRS score. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 to 6: 0. No Symptoms, 1. No Significant Disability, 2. Slight Disability, 3. Moderate Disability, 4. Moderately Severe Disability, 5. Severe Disability and 6. Dead.; (Stage 1 patients only had 30 day scores, Stage 2 patients had 30 day, 90 day and 180 day scores collected)
180 Day Follow-Up Modified Rankin Scale (mRS) Score	180 days	180 day follow-up visit mRS score. The modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. It is scored from 0 to 6: 0. No Symptoms, 1. No Significant Disability, 2. Slight Disability, 3. Moderate Disability, 4. Moderately Severe Disability, 5. Severe Disability and 6. Dead.; (Stage 1 patients only had 30 day scores, Stage 2 patients had 30 day, 90 day and 180 day scores collected)
180 Day Follow-Up Glasgow Outcome Scale (GOS) Score	180 days	180 day follow-up visit GOS score. The GOS is a scale used to determine the degree of recovery from patients with brain injury. There are five categories: 1. Dead, 2. Vegetative State, 3. Severe Disability, 4. Moderate Disability and 5. Good Recovery.; (Stage 1 patients only had 30 day scores, Stage 2 patients had 30 day, 90 day and 180 day scores collected)

Trial Locations

Locations (25)

Loyola University Medical Center; 🇺🇸 Maywood, Illinois, United States

University of Maryland Medical Systems; 🇺🇸 Baltimore, Maryland, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

Mt. Sinai Medical Center; 🇺🇸 New York, New York, United States

Via Christi Regional Medical Center; 🇺🇸 Wichita, Kansas, United States

Henry Ford Hospital; 🇺🇸 Detroit, Michigan, United States

University of Alabama at Birmingham; 🇺🇸 Birmingham, Alabama, United States

Wayne State University; 🇺🇸 Detroit, Michigan, United States

University of Cincinnati; 🇺🇸 Cincinnati, Ohio, United States

University of Texas HSC, San Antonio; 🇺🇸 San Antonio, Texas, United States

Hartford Hospital; 🇺🇸 Hartford, Connecticut, United States

Foothills Medical Centre; 🇨🇦 Calgary, Alberta, Canada

Medical College of Wisconsin; 🇺🇸 Milwaukee, Wisconsin, United States

Temple University; 🇺🇸 Philadelphia, Pennsylvania, United States

Standford Medical Center; 🇺🇸 Palo Alto, California, United States

CR Drew Medical Center; 🇺🇸 Los Angeles, California, United States

Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States

St. Louis University; 🇺🇸 Saint Louis, Missouri, United States

INOVA Fairfax Medical Center; 🇺🇸 Fairfax, Virginia, United States

University of Virginia, Charlottesville; 🇺🇸 Charlottesville, Virginia, United States

Newcastle General Hospital; 🇬🇧 Newcastle upon Tyne, United Kingdom

University of Heidelberg; 🇩🇪 Heidelberg, Germany

Albany Medical Center; 🇺🇸 Albany, New York, United States

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States

Medical University of South Carolina; 🇺🇸 Charleston, South Carolina, United States